Ximbio Release: Company Opens North America Office in Cambridge, Massachusetts
LONDON, January 18, 2017 /PRNewswire/ --
Ximbio, a non-profit online one-stop-shop for the global life science community to share research resources, has opened its first North American headquarters in Kendall Square, Cambridge, Massachusetts.
This marks an expansion for Ximbio following its launch in October 2014 as a business unit of UK- based company Cancer Research Technology (CRT), the commercialization arm of the foundation Cancer Research UK.
Ximbio.com allows scientists to find, source and share important research resources from cell lines, antibodies, proteins, microbes, small molecules and vectors to genomic models such as zebrafish and mice.
It sells and licenses them on behalf of academic institutes, onto the life science reagents market. Ximbio maintains the link between the product and the scientist and university that created them, so that they are credited for the research.
Melanie Hardman, Head of Ximbio, said: "We're delighted to expand to North America to continue our important work to get academically-funded research tools out of laboratory freezers and into the hands of other scientists - accelerating research.
"Our partnerships with non-profit research institutions create one of the most comprehensive collections of rare and unique biological materials available anywhere for the study and cure of disease."
The Ximbio, North America office will be headed by Robert Bondaryk, previously CEO at reagents company, Kerafast, senior VP & GM at genomic services company, Cogenics, and VP at laboratory supplies company, Fisher Scientific.
Robert Bondaryk, Head of Ximbio, North America, said: "I'm honored to be heading up this expansion into North America. Ximbio has extensive experience in managing research tools - with a portfolio exceeding 2,000 reagents available for commercialization and has signed over 700 agreements with more than 200 companies.
"And we're looking forward to working closely with academic and research laboratories in North America to build on this tremendous experience and success in Europe and beyond."
Ximbio, a non-profit online one-stop-shop for the global life science community to share research resources, has opened its first North American headquarters in Kendall Square, Cambridge, Massachusetts.
This marks an expansion for Ximbio following its launch in October 2014 as a business unit of UK- based company Cancer Research Technology (CRT), the commercialization arm of the foundation Cancer Research UK.
Ximbio.com allows scientists to find, source and share important research resources from cell lines, antibodies, proteins, microbes, small molecules and vectors to genomic models such as zebrafish and mice.
It sells and licenses them on behalf of academic institutes, onto the life science reagents market. Ximbio maintains the link between the product and the scientist and university that created them, so that they are credited for the research.
Melanie Hardman, Head of Ximbio, said: "We're delighted to expand to North America to continue our important work to get academically-funded research tools out of laboratory freezers and into the hands of other scientists - accelerating research.
"Our partnerships with non-profit research institutions create one of the most comprehensive collections of rare and unique biological materials available anywhere for the study and cure of disease."
The Ximbio, North America office will be headed by Robert Bondaryk, previously CEO at reagents company, Kerafast, senior VP & GM at genomic services company, Cogenics, and VP at laboratory supplies company, Fisher Scientific.
Robert Bondaryk, Head of Ximbio, North America, said: "I'm honored to be heading up this expansion into North America. Ximbio has extensive experience in managing research tools - with a portfolio exceeding 2,000 reagents available for commercialization and has signed over 700 agreements with more than 200 companies.
"And we're looking forward to working closely with academic and research laboratories in North America to build on this tremendous experience and success in Europe and beyond."